Valency requirements for B cell activation upon antigen encounter are poorly understood. OB1 transnuclear B cells express an IgG1 B cell receptor (BCR) specific for ovalbumin (OVA), the epitope of which can be mimicked using short synthetic peptides to allow antigen-specific engagement of the BCR. By altering length and valency of epitope-bearing synthetic peptides, we examined the properties of ligands required for optimal OB1 B cell activation. Monovalent engagement of the BCR with an epitope-bearing 17-mer synthetic peptide readily activated OB1 B cells. Dimers of the minimal peptide epitope oriented in an N to N configuration were more stimulatory than their C to C counterparts. Although shorter length correlated with less activation, a monomeric 8-mer peptide epitope behaved as a weak agonist that blocked responses to cell-bound peptide antigen, a blockade which could not be reversed by CD40 ligation. The 8-mer not only delivered a suboptimal signal, which blocked subsequent responses to OVA, anti-IgG, and anti-kappa, but also competed for binding with OVA. Our results show that fine-tuning of BCR-ligand recognition can lead to B cell nonresponsiveness, activation, or inhibition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920557PMC
http://dx.doi.org/10.1084/jem.20131603DOI Listing

Publication Analysis

Top Keywords

engagement bcr
12
monovalent engagement
8
transnuclear cells
8
cell activation
8
synthetic peptides
8
peptide epitope
8
bcr
4
bcr activates
4
activates ovalbumin-specific
4
ovalbumin-specific transnuclear
4

Similar Publications

Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and degraders/downregulators (SERMs and SERDs) show clinical efficacy, but responses are often non-durable.

View Article and Find Full Text PDF

Background: Persistent diabetes raises diabetic retinopathy (DR) risk, and management is challenging. Integrating transcriptomics and MR, this study provides a current reference for the clinical treatment of DR by identifying potential drug targets in adaptive immune response-associated genes (AIR-RGs).

Methods: The GSE102485 dataset about AIR-RGs and DR was downloaded from a public database.

View Article and Find Full Text PDF

Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients largely benefit from an expanding tyrosine kinase inhibitors (TKIs) toolbox that has improved the outcome of both diseases. However, TKI success is continuously challenged by mutation-driven acquired resistance and therefore, close monitoring of clonal genetic diversity is necessary to ensure proper clinical management and adequate response to treatment. Here, we report the case of a ponatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) patient harboring a BCR::ABL1 p.

View Article and Find Full Text PDF

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus.

Nat Rev Rheumatol

December 2024

AMPEL BioSolutions, Charlottesville, VA, USA.

Article Synopsis
  • Memory B cells in systemic lupus erythematosus (SLE) show dysfunction, being less responsive to B cell receptor (BCR) signaling but still reacting to other pathways like TLR and CD40-mediated activation.
  • Chronic exposure to specific autoantibodies and immune complexes may lead to a partially inactive state in these cells, allowing for continued production of harmful anti-RNP antibodies through a self-sustaining cycle of signaling.
  • Current treatments that aim at depleting B cells or targeting specific B cell receptors have shown limited success, suggesting a need to focus on addressing the dysfunction in memory B cells to better manage SLE without affecting non-involved B cell subsets.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!